Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week

Stock Information for Panbela Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Panbela Therapeutics Inc.

Panbela Provides Business Update and Reports Q1 2024 Financial Results
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Panbela Announces Poster Presentation at American Association for Cancer Research:
Panbela Announces Transfer to OTCQB Market
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.